UK’s VMD Approves Zoetis’ Lenivia: A New Long-Acting Monoclonal Antibody for Canine Osteoarthritis Pain

Zoetis has another tool in the osteoarthritis pain management conversation, and this one comes with a quarterly dosing schedule. The UK's Veterinary Medicines Directorate approved Lenivia (izenivetmab injection) on May 29, making it the first long-acting canine anti-nerve growth factor monoclonal antibody therapy cleared for once-every-three-months administration.

For dogs living with osteoarthritis, and for the clients managing their care at home, a single injection that provides three months of pain alleviation is a meaningful shift from current treatment rhythms.

How It Works

Lenivia targets nerve growth factor, a well-established mediator of both pain signaling and inflammation in the joint environment. By binding to NGF and reducing its downstream effects, the therapy interrupts a key pathway driving the chronic pain experience in dogs with osteoarthritis rather than simply masking symptoms at the surface level.

The anti-NGF mechanism is not new to veterinary medicine broadly, but Lenivia's approval as a long-acting formulation administered quarterly represents a distinct clinical profile from existing options in the UK market.

What the Field Study Showed

Zoetis says the therapy is backed by a decade of research and demonstrated effectiveness in improving mobility and reducing pain from the first injection in field studies. That first-injection response matters clinically because it shortens the window between initiation of therapy and observable improvement for both the patient and the client. Owners who see early results are more likely to stay consistent with treatment plans, which directly affects long-term outcomes in a chronic condition like OA.

Why This Approval Matters for Practice

Canine osteoarthritis is one of the most common chronic conditions seen in small animal practice, and pain management remains one of the most persistent challenges. The current toolkit includes NSAIDs, Librela (bedinvetmab, also an anti-NGF monoclonal antibody approved in the EU and UK), rehabilitation approaches, and multimodal protocols that vary widely by practice and patient. Adding a quarterly injectable monoclonal antibody with a demonstrated mechanism and field study data gives clinicians another option to individualize treatment, particularly for patients where owner compliance with daily oral medications is a limiting factor.

The approval is currently specific to the UK (GB) market. Zoetis regional president for Europe and the Middle East Julia von Gablenz described the clearance as a meaningful milestone in the company's continued innovation for canine osteoarthritis pain, noting that dogs with OA can experience persistent discomfort that affects comfort, mobility, and quality of life.

That last point is worth naming plainly. Osteoarthritis pain doesn't resolve on its own. Dogs don't report it the way humans do. The gap between when pain begins and when it gets addressed is often wider than anyone in the exam room is comfortable admitting. Tools that extend dosing intervals while maintaining efficacy have the potential to close that gap for patients whose owners are engaged but stretched thin.